Surgical Endoscopy

, Volume 25, Issue 2, pp 658–660

Extraperitoneal rectal cancer: why laparoscopic may be more effective than open surgery

Letter
  • 63 Downloads

References

  1. 1.
    Park IJ, Choi GS, Lim KH, Kang BM, Jun SH (2009) Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection. Surg Endosc 23(8):1818–1824CrossRefPubMedGoogle Scholar
  2. 2.
    Garber AM, Tunis SR (2009) Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 360(19):1925–1927CrossRefPubMedGoogle Scholar
  3. 3.
    Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J (2008) Long-term outcome of laparoscopic surgery for colorectal cancer: a Cochrane systematic review of randomised controlled trials. Cancer Treat Rev 34(6):498–504CrossRefPubMedGoogle Scholar
  4. 4.
    Ziogas D, Polychronidis A, Kanellos I, Roukos DH (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696 (author reply 697)CrossRefPubMedGoogle Scholar
  5. 5.
    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMedGoogle Scholar
  6. 6.
    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMedGoogle Scholar
  7. 7.
    Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRefGoogle Scholar
  8. 8.
    Ziogas D, Roukos D (2009) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRefGoogle Scholar
  9. 9.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830CrossRefPubMedGoogle Scholar
  10. 10.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMedGoogle Scholar
  12. 12.
    Roukos DH (2009) Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMedGoogle Scholar
  13. 13.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMedGoogle Scholar
  14. 14.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMedGoogle Scholar
  15. 15.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMedGoogle Scholar
  16. 16.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMedGoogle Scholar
  17. 17.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 (author reply 1363)CrossRefPubMedGoogle Scholar
  18. 18.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597CrossRefPubMedGoogle Scholar
  19. 19.
    Roukos DH, Lykoudis E, Liakakos T (2009) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361CrossRefGoogle Scholar
  20. 20.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMedGoogle Scholar
  21. 21.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMedGoogle Scholar
  22. 22.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197 (author reply 198)CrossRefPubMedGoogle Scholar
  23. 23.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMedGoogle Scholar
  24. 24.
    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMedGoogle Scholar
  25. 25.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141CrossRefPubMedGoogle Scholar
  26. 26.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):1555–1556PubMedGoogle Scholar
  27. 27.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMedGoogle Scholar
  28. 28.
    Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMedGoogle Scholar
  29. 29.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMedGoogle Scholar
  30. 30.
    Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280CrossRefPubMedGoogle Scholar
  32. 32.
    Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMedGoogle Scholar
  33. 33.
    Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMedGoogle Scholar
  34. 34.
    Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995CrossRefPubMedGoogle Scholar
  35. 35.
    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of SurgeryMetaxa Anticancer HospitalPeiraeusGreece
  2. 2.Department of General SurgeryUniversity Hospital of Heraklion, Medical School, University of CreteHeraklionGreece

Personalised recommendations